1
|
Xiao L, Liu D, Zuo S, Zhu X, Wang Y, Dong C. Urea-modulated UT-B urea transporter internalization is clathrin- and caveolae-dependent in infantile hemangioma-derived vascular endothelial cells. J Cell Biochem 2019; 120:5128-5136. [PMID: 30367514 DOI: 10.1002/jcb.27789] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Accepted: 09/10/2018] [Indexed: 11/10/2022]
Abstract
The aim of this study was to investigate the manner of urea-modulated UT-B urea transporter (UT) internalization in infantile hemangioma-derived vascular endothelial cells (HemECs). The immunohistochemistry assay was performed to identify infancy hemangioma-derived endothelial cell line (XPTS-1) cells. Cell toxicity was detected with the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Quantitative real-time polymerase chain reaction and Western blot analysis were measured to analyze the expression of UT-B. UT-B internalization was observed by confocal microscopy. The clathrin inhibitor chlorpromazine (CPZ) and caveolin endocytic disrupter methyl-β-cyclodextrin (MβCD) were used in XPTS-1 cells transfected with UT-B-GFP to repress endocytosis. Urea-promoted UT-B expression in a concentration-dependent manner in an infantile XPTS-1 cell line. CPZ and MβCD significantly inhibited UT-B protein internalization. The pretreatment of UT-B-GFP cells with adaptor protein2 (AP2)-μ2-siRNA and caveolin-siRNA significantly inhibited UT-B protein internalization. Our findings suggested that urea-mediated UT-B UT internalization is clathrin and caveolae dependent in infantile HemECs.
Collapse
Affiliation(s)
- Li Xiao
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Dakan Liu
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Song Zuo
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Xiaoshuang Zhu
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Yanlin Wang
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| | - Changxian Dong
- Department of Hemangioma, Henan Provincial People's Hospital, Zhengzhou, Henan, China
| |
Collapse
|
2
|
Lieberman R, Scoby C, Bacon P, Jackson MA. Visual Diagnosis: 7-week-old Girl with a Neck Mass. Pediatr Rev 2017; 38:e24-e27. [PMID: 28667242 DOI: 10.1542/pir.2016-0042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
| | | | - Patrick Bacon
- Department of Radiology, Children's Mercy Hospital and Clinics, Kansas City, MO
| | - Mary Anne Jackson
- Division of Infectious Diseases, Children's Mercy Hospital and Clinics; Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO
| |
Collapse
|
3
|
Asilian A, Mokhtari F, Kamali AS, Abtahi-Naeini B, Nilforoushzadeh MA, Mostafaie S. Pulsed dye laser and topical timolol gel versus pulse dye laser in treatment of infantile hemangioma: A double-blind randomized controlled trial. Adv Biomed Res 2015; 4:257. [PMID: 26918239 PMCID: PMC4746935 DOI: 10.4103/2277-9175.170682] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Accepted: 03/10/2013] [Indexed: 12/18/2022] Open
Abstract
Background: Infantile hemangioma (IH) is the most common tumor during infancy that usually appears as macular and gradually becomes a plaque or tumor. Approximately, 20% of all IH cases results in adverse effects and the Pulsed dye laser (PDL) 585 nm is a vascular laser leading to selective the micro vascular damage. Results of studies on non-selective B-blockers (e.g., timolol) indicate their effectiveness in preventing hemangioma growth. The aim of this study is a comparison of PDL plus timolol and PDL in the treatment of IH. Materials and Methods: This double-blind study was carried out on 30 infants (1-12 months old) and the patients were divided into two groups. Group A was treated with the four sessions PDL and the timolol gel 0.05% and Group B with PDL. Results: There were no differences in the mean age of patients for the diagnosis of hemangioma (Group A: 32.69 ± 24.64 days, Group B: 25.69 ± 21.16 days, P = 0.39) and the mean age at the start of the treatment (Group A: 148.125 ± 85.88 days, Group B: 146.25 ± 60.87 days, P = 0.94). There were a statistical difference in the mean of lesion size reduction (Group A: 17.62 ± 6.97 cm and Group B: 12 ± 5.71 cm, P = 0.018), mean percentage change in size mean (Group A: 71079 ± 23.41% and Group B: 54.59 ± 25.46%, P = 0.050) visual analog scale (Group A: 7.19 ± 1.51, Group B: 5.62 ± 1.78, P = 0.012) after treatment. There was no correlation between the time of beginning the treatment and the results (P = 0.857). Conclusions: Application of timolol with PDL is accompanied by the highest efficacy, cost benefits and the short time of treatment.
Collapse
Affiliation(s)
- Ali Asilian
- Department of Dermatology, Tehran University of Medical Sciences, Isfahan, Iran; Skin Diseases and Leishmaniasis Research Center, Tehran University of Medical Sciences, Tehran, Iran; Isfahan University of Medical Sciences, Isfahan, Iran
| | - Fatemeh Mokhtari
- Department of Dermatology, Tehran University of Medical Sciences, Isfahan, Iran; Isfahan University of Medical Sciences, Isfahan, Iran
| | - Atefeh Sadat Kamali
- Department of Dermatology, Tehran University of Medical Sciences, Isfahan, Iran; Isfahan University of Medical Sciences, Isfahan, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Bahareh Abtahi-Naeini
- Department of Dermatology, Tehran University of Medical Sciences, Isfahan, Iran; Isfahan University of Medical Sciences, Isfahan, Iran
| | - Mohammad Ali Nilforoushzadeh
- Skin Diseases and Leishmaniasis Research Center, Tehran University of Medical Sciences, Tehran, Iran; Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Shayan Mostafaie
- Isfahan University of Medical Sciences, Isfahan, Iran; Department of Epidemiology and Biostatistics, School of Public Health, Isfahan, Iran
| |
Collapse
|
4
|
Jeng MR, Fuh B, Blatt J, Gupta A, Merrow AC, Hammill A, Adams D. Malignant transformation of infantile hemangioma to angiosarcoma: response to chemotherapy with bevacizumab. Pediatr Blood Cancer 2014; 61:2115-7. [PMID: 24740626 DOI: 10.1002/pbc.25067] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2014] [Accepted: 03/24/2014] [Indexed: 12/13/2022]
Abstract
We describe a child initially diagnosed with multi-focal infantile hemangioma (cutaneous, hepatic, pulmonary), a benign vascular lesion, which underwent malignant transformation to angiosarcoma. The use of anti-angiogenic agents, such as bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, has been reported in adults with angiosarcoma. Treatment with chemotherapy (gemcitabine and docetaxel) and bevacizumab resulted in disease response with progression free survival of 12 months. This report describes the response to chemotherapy and bevacizumab in a child with angiosarcoma and highlights the potential for malignant transformation of benign vascular lesions and the need for careful monitoring.
Collapse
Affiliation(s)
- Michael R Jeng
- Division of Pediatric Hematology/Oncology/Stem Cell Transplantation/Cancer Biology, Stanford University School of Medicine, Palo Alto, California
| | | | | | | | | | | | | |
Collapse
|
5
|
Sethuraman G, Yenamandra VK, Gupta V. Management of infantile hemangiomas: current trends. J Cutan Aesthet Surg 2014; 7:75-85. [PMID: 25136206 PMCID: PMC4134656 DOI: 10.4103/0974-2077.138324] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Infantile hemangiomas (IH) are common vascular tumours. IH have a characteristic natural course. They proliferate rapidly during the early infantile period followed by a period of gradual regression over several years. Most of the uncomplicated IH undergo spontaneous involution, with a small proportion of cases requiring intervention. These are children with IH in life-threatening locations, local complications like haemorrhage, ulceration and necrosis and functional or cosmetic disfigurements. Systemic corticosteroids have been the first line of treatment for many years. Recently, non-selective beta-blockers, such as oral propranalol and topical timolol, have emerged as promising and safer therapies. Other treatment options include interferon α and vincristine which are reserved for life-threatening haemangiomas that are unresponsive to conventional therapy. This review mainly focuses on the current trends and evidence-based approach in the management of IH.
Collapse
Affiliation(s)
- Gomathy Sethuraman
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
| | - Vamsi K Yenamandra
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
| | - Vishal Gupta
- Department of Dermatology and Venereology, All India Institute of Medical Sciences, New Delhi, India
| |
Collapse
|
6
|
Wang Z, Li J, Xu X, Duan X, Cao G. Urea immunoliposome inhibits human vascular endothelial cell proliferation for hemangioma treatment. World J Surg Oncol 2013; 11:300. [PMID: 24266957 PMCID: PMC4222881 DOI: 10.1186/1477-7819-11-300] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Accepted: 11/17/2013] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Urea injection has been used in hemangioma treatment as sclerotherapy. It shrinks vascular endothelial cells and induces degeneration, necrosis, and fibrosis. However, this treatment still has disadvantages, such as lacking targeting and difficulty in controlling the urea dosage. Thus, we designed a urea immunoliposome to improve the efficiency of treatment. METHODS The urea liposome was prepared by reverse phase evaporation. Furthermore, the urea immunoliposome was generated by coupling the urea liposome with a vascular endothelial growth factor receptor (VEGFR) monoclonal antibody using the glutaraldehyde cross-linking method. The influence of the urea immunoliposome on cultured human hemangioma vascular endothelial cells was observed preliminarily. RESULTS Urea immunoliposomes showed typical liposome morphology under a transmission electron microscope, with an encapsulation percentage of 54.4% and a coupling rate of 36.84% for anti-VEGFR. Treatment with the urea immunoliposome significantly inhibited the proliferation of hemangioma vascular endothelial cells (HVECs) in a time- and dose-dependent manner. CONCLUSIONS The urea immunoliposome that we developed distinctly and persistently inhibited the proliferation of HVECs and is expected to be used in clinical hemangioma treatment.
Collapse
Affiliation(s)
- Zhiliang Wang
- Department of General Surgery, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an 710004, China.
| | | | | | | | | |
Collapse
|
7
|
|
8
|
Haught EAS, Johnson MC, Witt PD. Congenital Erythroleukemia Presenting as a Congenital Infantile Hemangioma. Plast Reconstr Surg 2007; 119:70e-72e. [PMID: 17496582 DOI: 10.1097/01.prs.0000254527.05283.f4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Affiliation(s)
- Elliott A S Haught
- Fresno, Calif. From the Departments of Pediatric Plastic Surgery and Pediatric Oncology, Children's Hospital Central California, University of California, San Francisco, Fresno
| | | | | |
Collapse
|
9
|
Türker M, Irken G, Oren H, Yilmaz S, Yüksel F, Olgun N. Evaluation of plasma tissue factor and tissue factor pathway inhibitor levels in childhood hemangiomas. Pediatr Blood Cancer 2006; 47:914-7. [PMID: 16395682 DOI: 10.1002/pbc.20729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
BACKGROUND The purpose of the study was to evaluate the plasma levels of tissue factor (TF), an angiogenic marker, and tissue factor pathway inhibitor (TFPI), an antiproliferative protein, in the childhood hemangiomas at proliferative and regressive stages. PROCEDURE The study included 30 patients with hemangiomas and 30 healthy children. Localization, number, stage, type, duration of growth, and complications of the hemangiomas were determined. Venous blood samples from all individuals were collected into citrated tubes and centrifuged. Supernatant plasma was separated, aliquated, and stored at -70 degrees C until samples could be assayed. Plasma levels of TF and TFPI were measured with quantitative ELISA kits. RESULTS Plasma TF and TFPI levels did not show any significant difference between the study and control groups. When plasma TF and TFPI levels of the children in the control group and in the study group who were in proliferative and regressive stage were compared to each other, no statistically significant difference could be detected. CONCLUSIONS Plasma TF and TFPI levels of our patients with hemangiomas were not different from healthy children and they did not show any significant difference in proliferative and regressive stages.
Collapse
Affiliation(s)
- Meral Türker
- Department of Pediatric Hematology, Dokuz Eylül University Faculty of Medicine, Izmir, Turkey
| | | | | | | | | | | |
Collapse
|
10
|
Dompmartin A, Boon LM, Labbé D. [Infantile hemangiomas: differential diagnosis and associated anomalies]. ANN CHIR PLAST ESTH 2006; 51:300-9. [PMID: 17007985 DOI: 10.1016/j.anplas.2006.07.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Infantile hemangiomas are frequent benign vascular tumors that are often easily recognized. However, the diagnosis between infantile hemangiomas and other vascular tumors, whether benign or malignant, may be difficult. This chapter describes the different clinical presentations of hemangiomas and details the investigations that are needed to confirm the nature of the lesion and to diagnose the potentially associated anomalies. Knowledge on differential diagnosis enables clinicians to detect hemangiomas that can lead to complications and that necessitate a multidisciplinary approach.
Collapse
Affiliation(s)
- A Dompmartin
- Service de dermatologie, centre hospitalier universitaire de Caen, avenue Georges-Clemenceau, 14033 Caen cedex, France.
| | | | | |
Collapse
|
11
|
Trager JDK. What's your diagnosis? A 3-month-old girl with an ulcerated perineal plaque. J Pediatr Adolesc Gynecol 2005; 18:409-13. [PMID: 16338607 DOI: 10.1016/j.jpag.2005.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Abstract
PURPOSE OF REVIEW Patients with vascular and lymphatic anomalies are often 'medical orphans' ascertained through distinct medical specialists. Multidisciplinary vascular anomalies programs provide focused expertise in diagnosis and treatment for patients. National and international workshops on vascular anomalies are fostering clinical and basic science research to enhance our understanding of vascular development and vascular anomalies. Herewith is presented an update of recent advances in the study of vascular/lymphatic anomalies. RECENT FINDINGS New original findings include (1) the identification of distinct cell surface markers and other cellular properties in hemangiomas and vascular malformations relevant to vascular development, (2) the discovery of novel genetic mutations and susceptibility genes in patients with vascular anomalies, (3) recognition of new risk stratifications and clinical issues for patients with hemangiomas and vascular malformations, and (4) the elucidation of sequelae from the disorders as well as side effects of recent and previous therapies for vascular anomalies. SUMMARY Vascular anomalies are an attractive model for the study of human disorders of vasculogenesis and angiogenesis. The etiology of these disorders is unclear and likely represents a multifactorial process. Clinical clues are leading to scientific investigations that may enable targeted therapies, prevention strategies, or both.
Collapse
Affiliation(s)
- Francine Blei
- Department of Pediatrics, Stephen D. Hassenfeld Center of NYU Medical Center, New York, New York 10016, USA.
| |
Collapse
|